

(12) International Application Status Report

Received at International Bureau: 16 May 2020 (16.05.2020)

Information valid as of: 18 February 2021 (18.02.2021)

Report generated on: 07 March 2021 (07.03.2021)

(10) Publication number:

WO2020/223576

(43) Publication date:

05 November 2020 (05.11.2020)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/US2020/030884

(22) Filing Date:

30 April 2020 (30.04.2020)

(25) Filing language:

English (EN)

(31) Priority number(s):

62/840,878 (US)

(31) Priority date(s):

30 April 2019 (30.04.2019)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

C12Q 1/6809 (2018.01); *C12Q 1/6883* (2018.01)

(71) Applicant(s):

LARIMAR THERAPEUTICS, INC. [US/US]; Three Bala Plaza East Suite 506 Bala Cynwyd, PA 19004 (US) *(for all designated states)*

(72) Inventor(s):

BETTOUN, Joan, David; 554 Manayunk Road Merion Station, PA 19066 (US)

(74) Agent(s):

MELLO, Jill, Ann; McCarter & English, LLP 265 Franklin Street Boston, MA 02110 (US)

(54) Title (EN): FRATAXIN-SENSITIVE MARKERS FOR DETERMINING EFFECTIVENESS OF FRATAXIN REPLACEMENT THERAPY

(54) Title (FR): MARQUEURS SENSIBLES À LA FRATAXINE POUR DÉTERMINER L'EFFICACITÉ D'UNE THÉRAPIE DE REMPLACEMENT DE FRATAXINE

(57) Abstract:

(EN): The present disclosure is based, at least in part, on providing a set of markers, also referred to herein as FXN-sensitive genomic markers (or FSGMs), the respective expression levels of which are positively or negatively correlated to frataxin (FXN) levels in a cell. Therefore, these FSGMs can be used to determine, evaluate, and/or monitor the effectiveness of FXN replacement therapy in a subject.

(FR): La présente invention est basée, au moins en partie, sur la fourniture d'un ensemble de marqueurs, également désignés ici comme marqueurs génomiques sensibles à FXN (ou FSGM) dont les niveaux d'expression respectifs sont corrélés positivement ou négativement aux niveaux de frataxine (FXN) dans une cellule. Par conséquent, ces FSGM peuvent être utilisés pour déterminer, évaluer et/ou surveiller l'efficacité de la thérapie de remplacement de FXN chez un sujet.

International search report:

Received at International Bureau: 09 September 2020 (09.09.2020) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA,

PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:

Declaration made as applicant's entitlement, as at the international filing date, to apply for and be granted a patent (Rules 4.17(ii) and 51bis.1(a)(ii)), in a case where the declaration under Rule 4.17(iv) is not appropriate

Declaration made as applicant's entitlement, as at the international filing date, to claim the priority of the earlier application, where the applicant is not the applicant who filed the earlier application or where the applicant's name has changed since the filing of the earlier application (Rules 4.17(iii) and 51bis.1(a)(iii))